BIM 28011

Drug Profile

BIM 28011

Latest Information Update: 04 May 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biomeasure Inc
  • Class Growth factors; Hormones
  • Mechanism of Action Growth hormone releasing factor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Dwarfism; Skin ulcer; Turner's syndrome

Most Recent Events

  • 12 Sep 2000 No-Development-Reported for Skin ulcer in France (Unknown route)
  • 12 Sep 2000 No-Development-Reported for Turner's syndrome in France (Unknown route)
  • 29 Apr 1997 Phase-I clinical trials for Turner's syndrome in France (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top